Knockdown of CABYR-a/b increases chemosensitivity of human non-small cell lung cancer cells through inactivation of Akt

Molecular Cancer Research

Volumn 12, Issue 3, 2014, Pages 335-347

  Qian, Zunlei ^a   Li, Min ^a   Wang, Rui ^a   Xiao, Qianqian ^a   Wang, Jing ^a   Li, Mingying ^a   He, Dacheng ^b   Xiao, Xueyuan ^a  

^a BEIJING NORMAL UNIVERSITY   (China)

^b Universities' Confederated Institute of Proteomics   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CABYR A PROTEIN; CABYR B PROTEIN; CALCIUM BINDING PROTEIN; CISPLATIN; PACLITAXEL; PROTEIN KINASE B; PROTEIN P27; PROTEIN P53; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VINCRISTINE; VINDESINE; CABYR PROTEIN, HUMAN; ISOPROTEIN; PHOSPHOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG RESPONSE; ENZYME INACTIVATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSIENT TRANSFECTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CARCINOMA, NON-SMALL-CELL LUNG; CELL GROWTH; DEFICIENCY; DISEASE COURSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; LUNG NEOPLASMS; METABOLISM; NUDE MOUSE; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CALCIUM-BINDING PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CISPLATIN; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; MICE, INBRED BALB C; MICE, NUDE; PACLITAXEL; PHOSPHOPROTEINS; PROTEIN ISOFORMS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897097510     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-13-0391     Document Type: Article

References (28)

1. Walters S, Maringe C, Coleman MP, Peake MD, Butler J, Young N, et al. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007. Thorax 2013;68:551-64.
2. Cosaert J, Quoix E. Platinum drugs in the treatment of non-small-cell lung cancer. Br J Cancer 2002;87:825-33. (Pubitemid 35252956)
3. Seve P, Dumontet C. Chemoresistance in non-small cell lung cancer. Curr Med Chem Anticancer Agents 2005;5:73-88. (Pubitemid 40081296)
4. Yokoe T, Tanaka F, Mimori K, Inoue H, Ohmachi T, Kusunoki M, et al. Efficient identification of a novel cancer/testis antigen for immunotherapy using three-step microarray analysis.CancerRes 2008;68:1074-82. (Pubitemid 351272225)
5. Duan Z, Duan Y, Lamendola DE, Yusuf RZ, Naeem R, Penson RT, et al. Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res 2003;9:2778-85. (Pubitemid 36842124)
6. Kasuga C, Nakahara Y, Ueda S, Hawkins C, Taylor MD, Smith CA, et al. Expression of MAGE and GAGE genes in medulloblastoma and modulation of resistance to chemotherapy, Laboratory investigation. J Neurosurg Pediatr 2008;1:305-13. (Pubitemid 351534716)
7. Kim Y, Park H, Park D, Lee YS, Choe J, Hahn JH, et al. Cancer/testis antigen CAGE exerts negative regulation on p53 expression through HDAC2 and confers resistance to anti-cancer drugs. J Biol Chem 2010;285:25557-68.
8. Naaby-Hansen S, Mandal A, Wolkowicz MJ, Sen B, Westbrook VA, Shetty J, et al. CABYR, a novel calcium-binding tyrosine phosphorylation regulated fibrous sheath protein involved in capacitation. Dev Biol 2002;242:236-54. (Pubitemid 34163983)
9. Luo CL, Xiao XY, Liu DH, Chen SS, Li MY, Xu AJ, et al. CABYR is a novel cancer-testis antigen in lung cancer. Clin Cancer Res 2007;13:1288-97.
10. Hsu HC, Lee YL, Cheng TS, Howng SL, Chang LK, Lu PJ, et al. Characterization of two non-testis-specific CABYR variants that bind to GSK3β with a proline-rich extensin-like domain. Biochem Biophys Res Commun 2005;329:1108-17.
11. Tseng YT, Hsia JY, Chen CY, Lin NT, Chong PC, Yang CY. Expression of the sperm fibrous sheath protein CABYR in human cancers and identification of a-enolase as an interacting partner of CABYR-a. Oncol Rep 2011;25:1169-75.
12. Li H, Fang L, Xiao X, Shen L. The expression and effects the CABYR-c transcript of CABYR gene in hepatocellular carcinoma. Bull Cancer 2012;99:E26-33.
13. Gray MJ, Wey JS, Belcheva A, McCarty MF, Trevino JG, Evans DB, et al. Neuropilin-1 suppresses tumorigenic properties in a human pancreatic adenocarcinoma cell line lacking neuropilin-1 coreceptors. Cancer Res 2005;65:3664-70. (Pubitemid 40616343)
14. Gurpinar E, Grizzle WE, Shacka JJ, Mader BJ, Li N, Piazza NA, et al. A novel sulindac derivative inhibits lung adenocarcinoma cell growth through suppression of Akt/mTOR signaling and induction of autophagy. Mol Cancer Ther 2013;12:663-74.
15. Guo Y, Du J, Kwiatkowski DJ. Molecular dissection of Akt activation in lung cancer cell lines. Mol Cancer Res 2013;11:282-93.
16. Scrima M, Marco CD, Fabiani F, Franco R, Pirozzi G, Rocco G, et al. Signaling networks associated with Akt activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydylinositol-3 kinase. PLoS ONE 2012;7:e30427.
17. Lee MW, Kim DS, Lee JH, Lee BS, Lee SH, Jung HL, et al. Roles of Akt1 and Akt2 in non-small cell lung cancer cell survival, growth, and migration. Cancer Sci 2011;102:1822-8.
18. Toulany M, Kehlbach R, Florczak U, Sak A, Wang S, Chen J, et al. Targeting of Akt1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair. Mol Cancer Ther 2008;7:1772-81.
19. Wang H, Galbán S, Wu R, Bowman BM, Witte A, Vetter k, et al. Molecular imaging reveals a role for AKT in resistance to cisplatin for ovarian endometrioid adenocarcinoma. Clin Cancer Res 2013;19:158-69.
20. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001;61:3986-97. (Pubitemid 32720961)
21. Dillon RL, Muller WJ. Distinct biological roles for the Akt family in mammary tumor progression. Cancer Res 2010;70:4260-4.
22. Lee MW, Kim DS, Min NY, Kim HT. Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin. Int J Cancer 2008;122:2380-4.
23. Huisman C, Ferreira CG, Bröker LE, Rodriguez JA, Smit EF, Postmus PE, et al. Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line NCI-H460. Clin Cancer Res 2002;8:596-606. (Pubitemid 34193982)
24. Kuroda H, Takeno M, Murakami S, Miyazawa N, Kaneko T, Ishigatsubo Y. Inhibition of heme oxygenase-1 with an epidermal growth factor receptor inhibitor and cisplatin decreases proliferation of lung cancer A549 cells. Lung Cancer 2010;67:31-6.
25. Brognard J, Sierecki E, Gao T, Newton AC. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 2007;25:917-31. (Pubitemid 46436532)
26. Maira SM, Galetic I, Brazil DP, Kaech S, Ingley E, Thelen M, et al. Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane. Science 2001;294:374-80. (Pubitemid 32963405)
27. Kawase T, Ohki R, Shibata T, Tsutsumi S, Kamimura N, Inazawa J, et al. PH domain-only protein PHLDA3 is a p53-regulated repressor of Akt. Cell 2009;136:535-50.
28. Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 2009;16:259-66.